Bio-Rad Laboratories (BIO.B) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pacific Biosciences of California (PACB) has outperformed Bio-Rad Laboratories (BIO.B) over the past year, gaining 52.3% versus a gain of 28.2%. Over five years, BIO.B leads with a -50.5% price change compared with -90.4% for PACB. Bio-Rad Laboratories is the larger company by market cap ($9.76 billion vs $724.2 million), about 13.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO.B | PACB |
|---|---|---|
| Share price | $365.08 | $2.33 |
| Market cap | $9.76B | $724.24M |
| 1-day change | 0.00% | +1.30% |
| YTD return | +17.50% | +24.60% |
| 1-year return | +28.15% | +52.29% |
| 5-year return | -50.54% | -90.45% |
| P/E ratio (TTM) | 46.27 | — |
| EPS (TTM) | $7.89 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | — |
| Revenue growth (YoY) | +0.65% | — |
| Net income (latest FY) | $759.90M | — |
| Gross margin | 51.87% | — |
| Operating margin | 1.83% | — |
| Net margin | 29.42% | — |
| 52-week high | $365.08 | $3.44 |
| 52-week low | $244.54 | $1.07 |
| Distance from 52-week high | 0.00% | -32.27% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +3.00% |
| Average volume | 4 | 10.39M |
| Shares outstanding | 5.06M | 310.83M |
| Employees | 7,450 | 485 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories is about 13.5 times larger than Pacific Biosciences of California by market value ($9.76B vs $724.24M).
- PACB has outperformed BIO.B by 24.1 percentage points over the past year.
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Healthcare · Medical Devices · 485 employees
BIO.B vs PACB FAQ
Which is bigger, Bio-Rad Laboratories or Pacific Biosciences of California?
Bio-Rad Laboratories (BIO.B) is larger, with a market capitalization of $9.76B compared with $724.24M for Pacific Biosciences of California (PACB).
Which stock has performed better over the past year, BIO.B or PACB?
PACB returned +52.29% over the past 12 months, compared with +28.15% for BIO.B (price return, excluding dividends). Past performance does not predict future results.
Are Bio-Rad Laboratories and Pacific Biosciences of California in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.